Xinan Sheng
Peking University(CN)University of Macau(MO)National Medical Products Administration(CN)National Health and Family Planning Commission(CN)Peking University Cancer Hospital(CN)National Institutes for Food and Drug Control(CN)Guizhou Electric Power Design and Research Institute(CN)Ministry of Education(ET)Qilu Hospital of Shandong University(CN)Zhejiang University of Technology(CN)Xinxiang Medical University(CN)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, Renal cell carcinoma treatment, Melanoma and MAPK Pathways
Most-Cited Works
- → Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification(2011)674 cited
- → Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases(2011)399 cited
- → Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma(2020)271 cited
- → Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort(2011)264 cited
- → Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma(2011)251 cited
- → Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma